Lauren Riker - Jul 28, 2021 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Vice President, Finance
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Jul 28, 2021
Transactions value $
-$125,096
Form type
4
Date filed
7/30/2021, 04:21 PM
Previous filing
Jun 11, 2021
Next filing
Jan 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $26.1K +2.41K +18.32% $10.81 15.6K Jul 28, 2021 Direct F1, F2
transaction PCRX Common Stock Sale -$147K -2.41K -15.49% $60.85 13.2K Jul 28, 2021 Direct F1, F3
transaction PCRX Common Stock Options Exercise $973 +90 +0.68% $10.81 13.2K Jul 29, 2021 Direct F1
transaction PCRX Common Stock Sale -$5.47K -90 -0.68% $60.81 13.2K Jul 29, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2.41K -16.85% $0.00 11.9K Jul 28, 2021 Common Stock 2.41K $10.81 Direct F4
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -90 -0.76% $0.00 11.8K Jul 29, 2021 Common Stock 90 $10.81 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2 Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.81 to $60.858, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.